News

March 2nd, 2021

Antibody Drug Conjugates as a New Class of Agents in Treating Recurrent Ovarian Cancer

March 2nd, 2021

GOG-P - Improving Care of Women’s Cancer - TiP of the Iceberg, An Independent Satellite Symposium during The SGO Annual Virtual Meeting on Women’s Cancer® - March 24th

February 3rd, 2021

A discussion with Dr. Previs & Dr. Tewari on actively accruing GYN Clinical Trials

January 27th, 2021

Advances in The Systemic Treatment of Cervical Cancer Through Clinical Trials

January 5th, 2021

GOG Foundation Virtual “Dinner” Meeting

December 17th, 2020

A Message From Larry J. Copeland, MD President, GOG Foundation, Inc.

December 16th, 2020

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 Study

December 9th, 2020

Verastem Oncology Initiates Phase 2 Registration-Directed Trial (GOG-3052) of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

June 22nd, 2020

GOG Foundation COVID-19 Guidance

Links to Guidance and Resources

June 3rd, 2020

Next NRG Oncology Meeting January 28-30, 2021